Thomas@yahoo
1日前
🤗 Employees Stock Options ( RIGHT TO BUY) 👍
Employee Stock Option ( RIGHT TO BUY)
Dowling Joseph D Chief Executive Officer
Number of Derivative Securities to ACQUIRE (A) 3,000,000
TRANSACTION DATE 02/18/2025
The option shares vest and BECOME EXERCISABLE in a series of thirty-six (36) successive equal monthly installments measured from FEBRUARY 18, 2025, provided there has not been a termination.of service as of such date.
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024328/ownership.html
Grasser Joerg Chief Financial Officer
Employee Stock Option (RIGHT TO BUY)
Number of Derivative Securities to ACQUIRE (A) 2,350,000
TRANSACTION DATE 02/18/2025
The option shares vest and become BECOME EXERCISABLE in a series of (36) successive equal monthly installments measured from FEBRUARY 18, 2025, provided there has not been a termination of service as of such date.
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024329/ownership.html
McCorkle William Director
Stock Option (RIGHT TO BUY)
Number of Derivative Securities to ACQUIRE (A) 500,000
Exercisable on April 30, 2026 “””
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024327/ownership.html
Corroon James Michael Jr. Director
Stock Option (RIGHT TO BUY)
Number of Derivative Securities to ACQUIRE (A) 500,000
Exercisable on April 30, 2026, “””
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024330/ownership.html
Wolf-man jack
1日前
WQLF SAYS: These options were not granted in 2021,2022 and 2023.
The following for 2025 options.
Joseph Dowling 3,000,000 Options
Over 36 months is 83,333 shares per month to be exercised. 83,333 multiplied by $.04 equals $3,333 per month. The shares added by the CEO, CFO and the two directors will cause dilution. The effect on their vesting if they sell on a monthly period in my opinion will not cause a downward effect on the price of the shares.
Joseph Dowling 3,000,000 Share Option and the 2,350,000 option shares for Joerg Grasser.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service.“
Here is the explanation for the two board of directors. 500,000 option shares for both directors.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2026, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
This is a schedule of shares granted in June 20, 2024 with explanation for Dowling, Grasser. McCorkle, and Corroon
Joseph Dowling
https://www.sec.gov/Archives/edgar/data/1510964/000095017024076906/xslF345X05/ownership.xml
Joerg Grasser
https://www.sec.gov/Archives/edgar/data/1763727/000095017024076912/xslF345X05/ownership.xml
For Dowling and Grasser
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from June 20, 2024, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
William McCorkle
https://www.sec.gov/Archives/edgar/data/1953074/000095017024076938/xslF345X05/ownership.xml
James Michael Corroon Jr.
https://www.sec.gov/Archives/edgar/data/1940094/000095017024076934/xslF345X05/ownership.xml
Explanation of Responses:
For Both McCorkle and Corroon.
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service”.
2025 Share Options
Thomas@yahoo
Re: Wolf-man jack post# 83760
Friday, 02/21/2025 5:11:01 AM
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024328/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024329/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024327/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024330/ownership.html
Bullish
BULLISH
Wolf-man jack
3日前
WQLF SAYS: Our story along with Tommy is the same. We bought high and cost averaged down. After my next buy if price stays the same will be identical with yours with the exception of you having a little over 100,000 shares from my treasure chest YQU Do Understand YQU understand.
Blue Duke of Earl
Here is what the additional $1.200,000 shark loan is for. It will keep the company in business for another 4 to 5 Quarters. Here is a breakdown of the cash burn in the past. In most cases it should be lower since the company has paid all of their past shark loans and acquisition costs. Cash at end of each Quarter and the Cash Burn per Quarter.
The Cash Burn for 2024 is around
$1,576,000. With the Quarter ending December 31,2024 of $752,00 plus the $1,190,000 from the shark loan comes to $1,,942,000. The difference will leave the company with $368,000 by the end of the first Quarter of 2026 (March 31,2026) . Starting in June the first payment on the shark loan will be made. There will be 10 payments made through March of 2026. The company needs to cut costs and raise revenue in the mean time. Hopefully our acquisitions can bring in the profits neede to continue without having to rely on another loan shark deal in 2026. By that time maybe the legislation in Congress will allow us to get a lower interest rate loans.
The bottom line is the loan is being utilized to keep the company in business.
10 payments at $106,667 comes to $1,066,670 which leaves us short of the $1,600,000 we owe by $533,330. This is where the cost cutting comes into play. With no lease payments for 10 months will help with that deficit.
December 31,2024 $752,000
$128,000 to $326,000 estimate
September 30, 2024 $979,000
$502,000
June 30, 2024 $477,000
$189,000
March 31, 2024 $662,000
$655,000
December 31,2023 $1,317,000
$326,000
September 30, 2023 $1,643,000
$41,000
June 30, 2023 $1,643,000
$534,000
March 31, 2023 $714,000
$103,009
December 31, 2022 $611,000
$528,000
September 30, 2022 $1,139,000
$25,000
June 30, 2022 $1,114,000
$1,325,000
March 31, 2022 $2,439,000
$1,067,999
December 31, 2021 $1,375,000
Wolf-man jack
4日前
WQLF SAYS: I wonder how much damages the company recovers. This could be the reason for the delay of the Lunar 🦊 Fox Trademark ™️ being registered ®️
Item 8.01 Other Events
On February 12, 2025, CV Sciences, Inc. (the “Company”) initiated an arbitration with JAMS asserting claims against its long-time legal counsel, Procopio, Cory, Hargreaves & Savitch LLP, and a former partner of that firm, who the Company had regarded as its general counsel (together “Procopio”). The Company’s engagement agreement with Procopio requires the resolution of such disputes through arbitration. Procopio provided the Company legal advice and guidance on when the Company’s former Chief Executive Officer and Board Chair, Michael J. Mona, Jr. (“Mona”), would recognize W-2 income and be subject to payroll and income tax withholding resulting from the settlement of restricted stock units (“RSUs”) previously awarded to Mona. According to Procopio, because Mona was then an insider within the meaning of Section 16(b) of the Securities Exchange Act of 1934 and he was subject to suit and disgorgement of short-swing profits if he sells stock within six months of the settlement date of the RSUs, Mona does not recognize W-2 income on the settlement date and that Mona would recognize W-2 income and be subject to tax withholding upon the expiration of the six month period under Section 16(b). Consequently, the Company issued to Mona a share certificate evidencing his ownership of shares of the Company’s stock then valued at more than $13 million that Mona constructively received upon the settlement of his RSUs without withholding taxes. After Mona received the certificate, without acknowledging its prior advice and guidance, Procopio changed its prior advise and advised the Company that tax withholding was required as of the settlement date. Procopio continued to represent the Company to resolve the lack of withholding, address the fallout therefrom, report the same in its periodic reports filed with the SEC and numerous other legal matters. The Company disclosed the lack of withholding in its Form 10-Q for the quarter ended, March 31, 2019, and in subsequent quarterly and annual reports. The Company has also disclosed in its prior reports filed with the SEC that the lack of withholding has been the subject of multiple legal proceedings, the most recent of which involved a case brought by Mona against the Company that was resolved in November 2024 in the Company’s favor in a binding arbitration. After that case was submitted to the arbitrator for decision, the Company sought to address with Procopio the legal advice and guidance it provided. Procopio responded by terminating the Company as a client on January 10, 2025, ending the Company’s 12-year relationship with Procopio as its legal counsel. The Company seeks to recover damages from Procopio resulting from its reliance on Procopio’s advice and guidance, including fees and expenses paid to Procopio and other professionals, expenses incurred by the Company and other harm to it.
https://www.sec.gov/Archives/edgar/data/1510964/000095017025022630/0000950170-25-022630-index.htm
Attorney of Record
Attorney Name: Neil A. Salyards Docket Number: 12041661US01
Attorney Primary Email Address: docketing@procopio.com Attorney Email Authorized: Yes
Correspondent
Correspondent Name/Address:
NEIL A. SALYARDS
PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
525 B STREET, SUITE 2200
SAN DIEGO, CALIFORNIA UNITED STATES 92101
Phone: 619-906-5639 Fax: 619-235-0398
Correspondent e-mail: docketing@procopio.com neil.salyards@procopio.com noel.gillespie@procopio.com emily.andelson@procopio.com
https://tsdr.uspto.gov/#caseNumber=98388857&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
Wolf-man jack
5日前
WQLF SAYS: I think the agreement acquisition with Extract Labs was a good mix if the major arrangement pertained to moving the companies headquarters to Colorado and the purpose of extracting some of our product line. The arrangement to run both companies with some identical products was my only drawback. We’ll see if the merger deal can still be done. The only drawback is the Extract Labs partnership with Higher Love Wellness. We do know one fact in the proposed merger is that Extract Labs And Lower Love Wellness had a combined annual sales lower than the mentioned earnout payment of $3,500,000. It appears that CV Sciences will break even if we can add another $1.5 to $2.0 million in annual revenue. I’m guessing that the two companies were going to bring around $2.0 to $2.5 million to the table. Maybe the fallout from the proposed acquisition may be a blessing in disguise. Imho Have Faith Have Patience Have Mercy WQLF Ahooooooo
“ In addition to the consideration payable at closing, and as further consideration for the Acquisition, the Sellers shall be entitled to receive up to two additional earnout payments payable in shares of restricted common stock of the Company (the “Earnout Amount”). The Earnout Amounts shall be based on Extract Labs’ Net Revenue (as defined in the Purchase Agreement) generated during the 12-month period following the closing date (for the first calculation period) or 24-month period following the closing date (for the second calculation period) and will be calculated as follows:
•
If Extract Labs’ Net Revenue is at least $4,600,000 in the relevant calculation period, then the Earnout Amount for such period will be $300,000.
•
If Extract Labs’ Net Revenue is at least $4,300,000 but less than $4,600,000 in the relevant calculation period, then the Earnout Amount for such period will be $200,000.
•
If Extract Labs’ Net Revenue is at least $4,000,000 but less than $4,300,000 in the relevant calculation period, then the Earnout Amount for such period will be $100,000.
•
If Extract Labs’ Net Revenue is at least $3,500,000 but less than $4,000,000 in the relevant calculation period, then the Earnout Amount for such period will be $50,000.
•
If Extract Labs’ Net Revenue is less than $3,500,000 in the relevant calculation period, then the Earnout Amount for such period will be $0.
Wolf-man jack
2週前
WQLF SAYS: The company will now save $400,000 and around 25 million shares of Dilution. What did Extract Labs have to offer in the short and long run YQU Now Understand YQU understand. Have Mercy WQLF Ahooooooo
On November 15, 2024, CV Sciences, Inc. (the “Company”) entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, Extract Labs, Inc., a Colorado corporation (“Extract Labs”), Craig Henderson (“Henderson”), and Higher Love Wellness Company, LLC (“HLWC” and together with Henderson, the “Sellers”),
https://www.extractlabs.com/higher-love-wellness/
https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/0000950170-24-129750-index.htm
Wolfman Jack Said; Time is Wasted Time you understand. Have Mercy Ahooooooo